Barclays lowered the firm’s price target on Karyopharm to $5 from $8 and keeps an Overweight rating on the shares post the Q3 report. The analyst de-risked the model but continues to see significant upside in the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on KPTI: